RA Capital Management

Activity from announced rounds

Activity in this selectionOct 22, 2026 · AI · Jul 25, 2026

RA Capital Management founds, funds and scales companies in healthcare and planetary health, combining scientific research with capital from seed through public-market financings.

Its TechAtlas research platform informs investment decisions through detailed scientific and market analysis. Raven, its healthcare incubator, works on originating and co-creating companies, giving researchers a route from a scientific idea to a funded business.

Blackbird provides a clinical development accelerator alongside the investment platform. These capabilities are relevant for founders who need to design a development programme and reach clinical milestones, as well as finance laboratory or commercial work.

Sources
Rounds participated in
2
Confirmed lead rounds
0
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$135M
2 disclosed · full round size, not this investor’s share

By stage

Series A1
Series B1

By primary sector

Biotech2

By country

United States2

Rounds

2 in this selection
Superluminal Medicines

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

$60MSeries B
Participant
Infinimmune

Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease

$75MSeries A
Role not disclosed